• 8 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Original Article
    Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model
    Aim: A model of progressively endocrine-resistant breast cancer was investigated to identify changes that can occur in signaling pathways after endocrine manipulation. Methods: The MCF7 breas [...] Read more.
    Kate M. Moore ... Simon P. Langdon
    Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:97–116
    DOI: https://doi.org/10.37349/etat.2022.00074
    This article belongs to the special issue Endocrine Resistant Breast Cancer
    View:1625
    Download:70
    Times Cited: 0
    Open Access
    Case Report
    Liver venous deprivation for resection of advanced hilar cholangiocarcinoma—a case report and review of the literature
    Hilar cholangiocarcinoma is a rare primary malignancy associated with a dismal prognosis. Currently, complete extended right or left-sided hepatectomy is the primary curative therapy. Achieving a ne [...] Read more.
    Radoslava Stoyanova ... Alexander Klaus
    Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:90–96
    DOI: https://doi.org/10.37349/etat.2022.00073
    This article belongs to the special issue Precision Medicine for Cholangiocarcinoma
    View:1398
    Download:51
    Times Cited: 0
    Open Access
    Review
    Targeting the two-pore channel 2 in cancer progression and metastasis
    The importance of Ca2+ signaling, and particularly Ca2+ channels, in key events of cancer cell function such as proliferation, metastasis, autophagy and angiogenesis, has recently begun to be appreciated. Of  [...] Read more.
    Kathryn A. Skelding ... Lisa F. Lincz
    Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:62–89
    DOI: https://doi.org/10.37349/etat.2022.00072
    This article belongs to the special issue Calcium Signaling Apparatus in Cancers
    View:2083
    Download:52
    Open Access
    Review
    Engineered phosphorus dendrimers as powerful non-viral nanoplatforms for gene delivery: a great hope for the future of cancer therapeutics
    During the past two decades, tremendous progress has been made in the dendrimer-based delivery of therapeutic molecules including, for instance, small molecules, macromolecules, and genes. This revi [...] Read more.
    Serge Mignani ... Jean-Pierre Majoral
    Published: February 25, 2022 Explor Target Antitumor Ther. 2022;3:50–61
    DOI: https://doi.org/10.37349/etat.2022.00071
    This article belongs to the special issue Gene Delivery Approach to Fight Cancer
    View:1451
    Download:44
    Open Access
    Original Article
    B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells
    Aim: T-helper cells could play an important role in the pathogenesis of chronic lymphocytic leukemia (CLL), a common B-cell neoplasm. Although CLL cells can present soluble antigens targeted from [...] Read more.
    Annabel R. Minton ... Graham Packham
    Published: February 25, 2022 Explor Target Antitumor Ther. 2022;3:37–49
    DOI: https://doi.org/10.37349/etat.2022.00070
    View:2125
    Download:68
    Open Access
    Review
    New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
    Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characterist [...] Read more.
    Kira-Lee Koster ... Markus Joerger
    Published: February 24, 2022 Explor Target Antitumor Ther. 2022;3:27–36
    DOI: https://doi.org/10.37349/etat.2022.00069
    This article belongs to the special issue Antibody-Drug Conjugates
    Open Access
    Original Article
    Bcl-2-like protein-10 increases aggressive features of melanoma cells
    Aim: B-cell lymphoma-2 (Bcl-2)-like protein-10 (Bcl2L10) is the less studied member of Bcl-2 family proteins, with the controversial role in different cancer histotypes. Very recently, Bcl2L10 ex [...] Read more.
    Donatella Del Bufalo ... Simona D’Aguanno
    Published: January 30, 2022 Explor Target Antitumor Ther. 2022;3:11–26
    DOI: https://doi.org/10.37349/etat.2022.00068
    This article belongs to the special issue The Role of Bcl-2 Family Proteins in Cancer Progression and Their Relevance to Cancer Therapy
    View:1957
    Download:71
    Times Cited: 0
    Open Access
    Review
    Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
    Targeted immunotherapy has arisen over the past decade to the forefront of cancer care. Notably, targeted therapies such as antibody-drug conjugates (ADCs) are becoming more recognized for a novel a [...] Read more.
    Monique Hartley-Brown, Paul Richardson
    Published: January 14, 2022 Explor Target Antitumor Ther. 2022;3:1–10
    DOI: https://doi.org/10.37349/etat.2022.00067
    This article belongs to the special issue Antibody-Drug Conjugates
    View:2832
    Download:118